SEC 13F Intelligence

Boxer Capital, LLC / ELVN

Boxer Capital, LLC’s Enliven Therapeutics Inc Position

Does Boxer Capital, LLC own Enliven Therapeutics Inc (ELVN)? Not currently — the last reported position was 671.4K shares worth $17M in Q3 2024; the fund’s latest 13F (Q4 2024) no longer reports it.

Position Value
$17M
Q3 2024
Shares
671.4K
% of Portfolio
+0.84%
Quarters Held
7
position exited

Position History ELVN

Reported value by quarter
Q1 ’23: $15,563Q1 ’23Q2 ’23: $14,504Q2 ’23Q3 ’23: $9MQ3 ’23Q4 ’23: $9MQ4 ’23Q1 ’24: $12MQ1 ’24Q2 ’24: $16MQ2 ’24Q3 ’24: $17MQ3 ’24filingsflow.com
QuarterSharesValue% of Portfolio
Q3 2024671.4K$17M+0.84%
Q2 2024671.4K$16M+0.83%
Q1 2024671.4K$12M+0.58%
Q4 2023646.1K$9M+0.45%
Q3 2023646.1K$9M+0.47%
Q2 2023710.6K$14,504+0.67%
Q1 2023710.6K$15,563+0.76%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Boxer Capital, LLC’s full portfolio or all institutional holders of ELVN.